Online citations, reference lists, and bibliographies.

Production Of Monoclonal Antibodies In Glycoengineered Pichia Pastoris

D. Zha, Thomas O. Linden, Thomas I. Potgieter
Published 2011 · Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Although improvements in antibody expression by mammalian cells are nearing maturation, efforts to improve antibody efficacy through glycoengineering are rapidly expanding. For example, the production of full length monoclonal antibodies with uniform human N-linked glycans by glycoengineered yeast has been used to optimize antibody effector function. The glycoengineered yeast expression platform not only enables elucidation of structure function relationships but also offers a robust and economically viable alternative to mammalian cell expression. This chapter provides an overview of glycobiology, engineering of P. pastoris to secrete recombinant proteins with uniform human N-linked glycans as well as bioprocess considerations in the production of full length monoclonal antibodies by a yeast based expression system.
This paper references
10.1021/bp040016j
Glycosylation of Recombinant Antibody Therapeutics
R. Jefferis (2005)
10.1016/S0167-7799(96)10062-7
Effect of glycosylation on antibody function: implications for genetic engineering.
A. Wright (1997)
10.1038/nbt1260
Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor
Kevin M. Cox (2006)
10.1016/J.FEMSYR.2004.06.016
Reliable high-throughput screening with Pichia pastoris by limiting yeast cell death phenomena.
R. Weis (2004)
10.1016/J.JCHROMB.2006.10.033
Future of antibody purification.
D. Low (2007)
10.1023/B:GLYC.0000043740.26062.2c
Structure, function and pathology of O-mannosyl glycans
T. Endo (2004)
10.1023/A:1008133914854
Recovery of mouse endostatin produced by Pichia pastoris using expanded bed adsorption
L. Trinh (2000)
10.1038/nbt0910-917
Biopharmaceutical benchmarks 2010
G. Walsh (2010)
10.1074/jbc.M403234200
Roles of O-Mannosylation of Aberrant Proteins in Reduction of the Load for Endoplasmic Reticulum Chaperones in Yeast*
K. Nakatsukasa (2004)
10.1038/6179
Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
P. Umaña (1999)
10.1002/BIT.20051
Methanol induction optimization for scFv antibody fragment production in Pichia pastoris
A. Cunha (2004)
10.1006/prep.1995.0013
Expression of a synthetic gene encoding the anticoagulant-antimetastatic protein ghilanten by the methylotropic yeast Pichia pastoris.
R. G. Brankamp (1995)
10.1016/j.coi.2008.06.007
Terminal sugars of Fc glycans influence antibody effector functions of IgGs.
T. Raju (2008)
10.1205/CERD.82.9.1144.44166
Bioreactor Retrofitting to Avoid Aeration with Oxygen in Pichia Pastoris Cultivation Processes for Recombinant Protein Production
M. Jenzsch (2004)
10.1385/1-59259-774-2:277
High-throughput expression in microplate format in Pichia pastoris.
M. Boettner (2004)
10.1080/02648725.2001.10648017
Industrial Purification of Pharmaceutical Antibodies: Development, Operation, and Validation of Chromatography Processes
R. L. Fahrner (2001)
10.1007/s10295-010-0746-1
High-throughput screening and selection of yeast cell lines expressing monoclonal antibodies
Gavin C. Barnard (2010)
10.2147/DDDT.S4378
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC
Akito Natsume (2009)
Biochemical engineering fundamentals
J. Bailey (1977)
10.1016/S1389-1723(00)80082-1
High level secretion of recombinant human serum albumin by fed-batch fermentation of the methylotrophic yeast, Pichia pastoris, based on optimal methanol feeding strategy.
K. Kobayashi (2000)
10.1021/bp050274w
Exploitation of the Adsorptive Properties of Depth Filters for Host Cell Protein Removal during Monoclonal Antibody Purification
Y. Yigzaw (2006)
10.1006/BIOL.1999.0179
Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing.
M. Schenerman (1999)
10.2174/138920108786786420
Editorial [Hot Topic: Therapeutic Antibodies and Derivatives: From the Bench to the Clinic(Guest Editor: Alain Beck)]
A. Beck (2008)
10.4161/mabs.1.5.9448
Industrialization of mAb production technology: The bioprocessing industry at a crossroads
B. Kelley (2009)
10.1016/j.fertnstert.2007.11.013
Efficacy of native and hyperglycosylated follicle-stimulating hormone analogs for promoting fertility in female mice.
R. Trousdale (2009)
10.1128/AEM.02106-07
Efficient Antibody Production upon Suppression of O Mannosylation in the Yeast Ogataea minuta
Kousuke Kuroda (2007)
10.1016/J.CHROMA.2006.11.075
Application of central composite design to the optimisation of aqueous two-phase extraction of human antibodies.
P. Rosa (2007)
10.1007/S004490050677
The optimal flow rate and column length for maximum production rate of protein A affinity chromatography
R. Fahrner (1999)
10.1038/nrmicro1087
The humanization of N-glycosylation pathways in yeast
S. Wildt (2005)
10.1002/1097-0290(20001005)70:1<1::AID-BIT1>3.0.CO;2-Y
Modeling Pichia pastoris growth on methanol and optimizing the production of a recombinant protein, the heavy-chain fragment C of botulinum neurotoxin, serotype A.
W. Zhang (2000)
10.1093/GLYCOB/12.4.43R
Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds.
R. Spiro (2002)
10.1002/BIT.20816
Comparison of different options for harvest of a therapeutic protein product from high cell density yeast fermentation broth
A. Wang (2006)
10.1016/j.jbiotec.2008.12.015
Production of monoclonal antibodies by glycoengineered Pichia pastoris.
Thomas I. Potgieter (2009)
10.1271/bbb.70080
Protein O-Glycosylation in Fungi: Diverse Structures and Multiple Functions
M. Goto (2007)
10.1016/S0167-7799(97)01045-7
Expanded-bed adsorption in industrial bioprocessing: recent developments.
R. Hjorth (1997)
10.1038/nri2206
Fcγ receptors as regulators of immune responses
F. Nimmerjahn (2008)
10.1186/1475-2859-9-61
Production of glycoprotein vaccines in Escherichia coli
J. Ihssen (2010)
10.1016/J.JBIOTEC.2007.05.019
A quantitative analysis of the benefits of mixed feeds of sorbitol and methanol for the production of recombinant avidin with Pichia pastoris.
C. Jungo (2007)
10.1016/j.tibtech.2009.01.004
Chromatography-free recovery of biopharmaceuticals through aqueous two-phase processing.
A. Azevedo (2009)
10.1038/mt.2009.37
Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease.
Yunxiang Zhu (2009)
10.1016/j.sbi.2003.09.003
O-mannosyl glycans: from yeast to novel associations with human disease.
T. Willer (2003)
10.1016/S1046-5928(02)00029-3
A micro-scale process for high-throughput expression of cDNAs in the yeast Saccharomyces cerevisiae.
C. Holz (2002)
10.1016/J.PEP.2007.10.001
High-yield recombinant expression of the extremophile enzyme, bee hyaluronidase in Pichia pastoris.
S. Reitinger (2008)
10.1016/j.copbio.2009.10.008
Expression systems for therapeutic glycoprotein production.
Y. Durocher (2009)
10.1517/17460440903413504
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins
A. Beck (2010)
10.1016/J.TIBTECH.2007.07.002
Selection methods for high-producing mammalian cell lines.
S. Browne (2007)
10.1016/S0021-9673(99)01119-X
Expanded-bed chromatography in primary protein purification.
F. B. Anspach (1999)
10.1002/bit.22756
Antibody expression kinetics in glycoengineered Pichia pastoris
Thomas I. Potgieter (2010)
10.1056/NEJM199105233242104
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
N. Barton (1991)
10.1021/bp990296g
Human Chymotrypsinogen B Production from Pichia pastoris by Integrated Development of Fermentation and Downstream Processing. Part 2. Protein Recovery
J. Thömmes (2001)
10.1093/GLYCOB/CWH104
Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose.
P. Bobrowicz (2004)
10.1006/PREP.2000.1276
Large-scale purification of recombinant human angiostatin.
S. Shepard (2000)
10.1007/BF00873690
Physiological and technological aspects of large-scale heterologous-protein production with yeasts
M. Hensing (2004)
10.1091/MBC.12.4.1093
O-mannosylation protects mutant alpha-factor precursor from endoplasmic reticulum-associated degradation.
C. Harty (2001)
10.1002/BIT.20851
Engineering of Pichia pastoris for improved production of antibody fragments
Brigitte Gasser (2006)
10.1038/nbt0410-307
Fresh from the biologic pipeline—2009
C. Sheridan (2010)
10.1016/0141-0229(84)90062-0
Continuous extraction of β-d-galactosidase from Escherichia coli in an aqueous two-phase system: effects of biomass concentration on partitioning and mass transfer
A. Veide (1984)
10.1126/SCIENCE.1088166
Production of Complex Human Glycoproteins in Yeast
S. R. Hamilton (2003)
10.1016/S0168-1656(02)00157-8
High-throughput screening for expression of heterologous proteins in the yeast Pichia pastoris.
M. Boettner (2002)
10.1021/bp025574h
High‐Level Expression of Recombinant IgG in the Human Cell Line PER.C6
D. Jones (2003)
10.1042/BJ20050364
Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice.
Yunxiang Zhu (2005)
10.1016/j.copbio.2009.10.009
Pharmacological significance of glycosylation in therapeutic proteins.
H. Li (2009)
10.1002/BIT.260110302
Measurement of heat evolution and correlation with oxygen consumption during microbial growth
C. Cooney (1969)
10.1016/J.ADDR.2006.05.002
Current and future issues in the manufacturing and development of monoclonal antibodies.
S. Kozlowski (2006)
10.1007/s10295-003-0089-2
Detection of non-host viable contaminants in Pichia pastoris cultures and fermentation broths
B. A. Plantz (2003)
10.1038/nbt0309-222
Fresh from the biologic pipeline
Randall E. Osborne (2009)
10.1038/nbt1178
Optimization of humanized IgGs in glycoengineered Pichia pastoris
H. Li (2006)
10.1007/s00253-006-0652-7
Cooverexpression of chaperones for enhanced secretion of a single-chain antibody fragment in Pichia pastoris
Leonardo M. Damasceno (2007)
Harvest and Recovery of Monoclonal Antibodies from Large-Scale Mammalian Cell Culture
A. Shukla (2008)
10.1093/glycob/cwp079
Optimal and consistent protein glycosylation in mammalian cell culture.
P. Hossler (2009)
10.1126/science.1130256
Humanization of Yeast to Produce Complex Terminally Sialylated Glycoproteins
S. R. Hamilton (2006)
10.1016/j.biologicals.2008.06.004
An overview of animal cell substrates for biological products.
John C. Petricciani (2008)
10.1016/S0032-9592(02)00097-3
Mass transfer in a spray column during two-phase extraction of horseradish peroxidase
N. D. Srinivas (2002)
10.1023/A:1012096020895
Routine manufacture of recombinant proteins using expanded bed adsorption chromatography
S. Shepard (2001)
10.1021/bp010041e
Scale‐Up of a High Cell Density Continuous Culture with Pichiapastoris X‐33 for the Constitutive Expression of rh‐Chitinase
B. Schilling (2001)
10.1016/J.JCHROMB.2006.09.026
Downstream processing of monoclonal antibodies--application of platform approaches.
A. Shukla (2007)
10.1002/BIT.21565
Influence of specific growth rate on specific productivity and glycosylation of a recombinant avidin produced by a Pichia pastoris Mut+ strain
J. Schenk (2008)
10.1016/J.JCHROMB.2004.01.008
Practical application of aqueous two-phase partition to process development for the recovery of biological products.
M. Rito‐Palomares (2004)
Trends and future prospects of aqueous two-phase extraction.
Kula Mr (1990)
10.1016/J.BIOCHI.2007.10.013
Novel long-lasting interferon alpha derivatives designed by glycoengineering.
N. Ceaglio (2008)
10.1073/pnas.0931263100
Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris
Byung-Kwon Choi (2003)
10.1021/bp070117s
Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations
B. Kelley (2007)
10.1038/nm0395-237
Glycosylation changes of IgG associated with rheumatooid arthritis can activate complement via the mannose-binding protein
R. Malhotra (1995)
10.1002/BIT.20811
Interfacing Pichia pastoris cultivation with expanded bed adsorption
M. Jahic (2006)
10.1517/14712598.7.9.1401
Antibody therapeutics:
R. Jefferis (2007)
10.1073/PNAS.0500044102
Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli.
M. Feldman (2005)
10.1055/S-2005-837653
Glyco-engineering of moss lacking plant-specific sugar residues.
C. M. Huether (2005)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar